Pharmaceutically acceptable phosphate-glycerol carrying bodies
AssigneeVasogen Ireland Limited
InventorsAnthony BOLTON, Arkady Mandel
Life of this patent
Estimating the term…
Abstract
This invention relates to three-dimensional synthetic and semi-synthetic compositions having biological activity, and to the uses thereof in the treatment and/or prophylaxis of various disorders in mammalian patients. More particularly it relates to preparations and uses of synthetic and semi-synthetic bodies, such as liposomes, which after introduction into the body of a patient, produce beneficial anti-inflammatory, organ protective and immune regulatory effects. The invention also relates to treatments and compositions for alleviating inflammatory and autoimmune diseases and their symptoms.
Claims16
1-52. (canceled)
A method for treating or prophylaxis of a mammalian cardiac disorder, the presence of or the susceptibility to which is detectable by observing a prolonged QT-c interval on an electrocardiogram of the patient, which method comprises administering to a mammalian patient suffering therefrom or susceptible thereto a pharmaceutical composition comprising an effective amount of pharmaceutically acceptable bodies, and a pharmaceutically acceptable carrier, wherein the surfaces of said bodies comprise an effective number of phosphate-glycerol groups to inhibit and/or reduce the progression of the cardiac disorder.
62-73. (canceled)
A method for treating or prophylaxis of a mammalian cardiac disorder, the presence of or the susceptibility to which is detectable by observing a prolonged QT-c interval on an electrocardiogram of the patient, which method comprises administering to a mammalian patient suffering therefrom or susceptible thereto a pharmaceutical composition comprising an effective amount of pharmaceutically acceptable bodies having a size of from about 20 nm to about 500 μm, and a pharmaceutically acceptable carrier, wherein the surfaces of said bodies comprise an effective number of phosphate-glycerol groups to inhibit and/or reduce the progression of the cardiac disorder.
Dependencies are inferred from the claim text.